Introduction: Non-alcoholic-fatty-liver-disease (NAFLD) encompasses a wide spectrum of diseases
that range from simple steatosis (NAFL) to steatosis with inflammation and fibrosis
(namely non-alcoholic steatohepatits or NASH) up to cirrhosis and hepatocellular carcinoma
(HCC). The greatest challenge in this field is to recognize the patient with a more
severe and/or progressive pathology. A reliable noninvasive method based on biomarkers
does not exist. Metabolomics is a novel and powerful method to discover biomarkers
and gives insights on diseases pathophysiology. Few studies have applied this technique
to NAFLD patients.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Digestive and Liver DiseaseAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
Article info
Identification
Copyright
© 2018 Published by Elsevier Inc.
